SANA Side Effects

Reported SANA side effects

Phase 1 trial (41 volunteers, up to 15 days of dosing) All human safety data come from one phase 1 trial in 41 volunteers, with at most 15 days of dosing (PMID: 40527924). Two participants had adverse events judged definitively related to SANA: reversible damage to the kidney tubules, seen as protein and glucose in the urine, after the highest single dose of 800 mg (PMID: 40527924). The safety review committee ended the single-dose part before the last participant in the 800 mg cohort was dosed; it judged that the no-observed-adverse-effect level had been determined (PMID: 40527924). No adverse events judged definitively drug-related occurred in the 15-day multiple-dose part of the SANA trial, and the most frequent possibly drug-related events were headache and soft stools (PMID: 40527924). No severe adverse events were recorded, liver function was normal in all participants after 15 days, and no moderate or severe gastrointestinal adverse effects were reported (PMID: 40527924). One participant in the lowest multiple-dose cohort was withdrawn because of mild proteinuria, which was judged unrelated to SANA and probably due to kidney disease missed at screening (PMID: 40527924). Participants reported no change in appetite or satiety on a questionnaire, and one participant in the highest-dose group had higher fasting glucose despite lower weight and insulin (PMID: 40527924). Animal data Eight weeks of SANA at 400 mg/kg a day in normal mice showed no signs of kidney or liver toxicity (PMID: 40527924). In mice lacking the mitochondrial creatine kinase CKMT1, SANA at room temperature was followed by a roughly 50 percent increase in mortality within a week, while no normal mice died, and housing at thermoneutrality prevented the deaths; the authors suggest SANA commits mice to creatine-dependent heat production at the expense of other heat-producing pathways (PMID: 40527924). In normal mice, SANA did not impair shivering, skeletal muscle creatine kinase or mitochondrial function, exercise capacity, or heart mitochondrial respiration and function, although it raised muscle creatine levels (PMID: 40527924). What is not known No human data on SANA beyond 15 days, in pregnancy, in children or with other medicines were found (PMID: 40527924).

When to continue, reduce, or stop SANA

SANA contraindications

SANA is an experimental compound with no approved label, so no official contraindications exist. The cautions below come from the phase 1 and animal findings and are reported as the sources state them. Kidney function warrants caution: the only adverse events judged definitively related to SANA in the phase 1 trial were reversible kidney tubule damage after a single 800 mg dose, and a participant with probable undetected kidney disease developed proteinuria during the trial (PMID: 40527924). Defects in creatine metabolism are a concern from animal work: in mice lacking the creatine kinase CKMT1, SANA at room temperature was followed by deaths that did not occur in normal mice (PMID: 40527924). SANA is built on the salicylate scaffold, the parent compound of aspirin (PMID: 40527924), and no study has tested SANA in people with aspirin or salicylate sensitivity. Pregnancy, children and long-term use fall outside the data: the SANA trial enrolled adults aged 18 to 60 for at most 15 days of dosing, and no data in pregnancy or in children were found (PMID: 40527924).

Why vendor quality drives SANA side-effect frequency

Research-compound communities consistently report that adverse-event frequency tracks with source quality. Three reasons: (1) impurity profiles vary by lab (residual synthesis byproducts can trigger reactions); (2) mislabeled mass means actual dose can be 50-150% of stated dose; (3) reconstitution-grade water and capping methodology affect long-term storage stability. COA-verified vendors with published HPLC data minimize all three failure modes. Check a vendor's COA record and Trust Score before you buy.

SANA side effects FAQ

Research-use disclaimer. All safety information on this page summarizes published research literature and community-reported reactions. It is not medical advice and not authorization for human consumption. Always consult a licensed practitioner before any compound enters a clinical context. Compounds linked from this page are sold for research-use only.
Affiliate disclosure. See our affiliate disclosure .